GUTS just delivered its first positive earnings surprise in recent memory — and then shorts started creeping back in.
Fractyl Health posted Q1 EPS of $0.06 against a consensus estimate of -$0.16, a rare beat for a pre-revenue biotech still burning cash. The stock closed at $0.734 on May 12, up 6% on the week despite a 4.6% pullback on the day after results. The one-month move is even more striking: the stock has rallied 60% in May, recovering from April lows that saw the share price under significant pressure. The real catalyst sitting on the horizon is the pivotal cohort data for Revita — expected in Q4 2026 — along with a potential De Novo regulatory reclassification that could reshape the clinical story.
The short-seller retreat over the past month tells a clear story. SI peaked near 4.3% of the free float in early April, then fell sharply through the month as the stock rebounded, landing at roughly 2.0% by May 12. That is a 50% decline in short positioning over 30 days. The borrow market reflects the same relaxation. Cost to borrow has eased from above 2.9% in early April to 2.1% now, down around 7% on the week. Availability is ample — at roughly 9% utilization of the lending pool, there is no squeeze dynamic at work. The ORTEX short score of 33.4 sits well below the midpoint of the 0-100 scale, meaning the overall short-positioning signal for GUTS is moderate at best.
On Monday, Fractyl also received clinical trial application authorisation in the Netherlands for a first-in-human Phase 1/2 study of RJVA-001, a gene therapy programme. The company flagged preliminary data in the second half of 2026. That announcement, combined with the earnings beat, drove the sharp compression in short interest seen over the week — SI rose 9.4% week-on-week in the most recent reading, a partial rebuild after the squeeze, but from a much lower base than April's highs.
The Street remains broadly supportive but the consensus is built on targets that look generous relative to the current price. Four analysts carry Buy ratings and the mean price target is $8.00, implying more than 1,000% return potential from the current $0.73 level — a gap that reflects clinical binary risk as much as conviction. Morgan Stanley's January 2026 downgrade to Equal-Weight with a $2.00 target remains the outlier bearish voice among rated analysts. The bull case rests entirely on Revita's weight-loss data and the RAPID regulatory pathway to expedite approval; the bear case centres on modest weight-loss results from small trials and uncertain commercial adoption even if the De Novo classification succeeds. With zero revenue and operating cash outflows running near $50 million annually, the runway to early 2027 gives Fractyl one credible window to deliver its pivotal data before the financing question returns.
The institutional picture shows a mix of conviction and patience. 683 Capital added aggressively — building from near zero to 6 million shares in the latest reported period. Vanguard also added 4.1 million shares. Marshall Wace came in with a fresh 5.9-million-share position. On the other side, Nantahala trimmed 2.4 million shares and Alyeska cut 1.8 million. The top-15 holders collectively control roughly 55% of outstanding shares, which means any meaningful catalyst could move the stock sharply in either direction on thin float.
The next scheduled earnings event is June 10. Between now and then, the RJVA-001 dosing timeline and any update on the Revita pivotal cohort timeline will be the primary variables worth tracking — not the headline short figure, which has normalised, but the clinical newsflow that still drives everything for this name.
See the live data behind this article on ORTEX.
Open GUTS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
